Search PubMed⌕ Search

Biomedical subjects

J Fries

Publications and source records attributed to J Fries.

At least 19 recordsLinked to original sources

[A rare case of birenal malacoplakia with renal failure].

HISTORY AND ADMISSION FINDINGS: A 45 year old man was admitted to our hospital because of fever, loss of appetite, and deterioration of general health. For two weeks the patient suffered from diarrhea which had resulted in moderate volume depletion. In addition, he complained of bilateral flank pain at the time of admission. Furthermore, the patient had a history of heavily drinking alcohol as well as cigarette smoking for many years. He had never attended a medical doctor before. INVESTIGATIONS: The patient presented with the clinical picture of acute renal failure and urosepticaemia which was caused by Escherichia coli. The kidneys were found to be at the upper limit of normal by sonography. Magnetic resonance imaging revealed signal-alterations in both kidneys with hyper- and hypointense zones in the renal parenchyma. DIAGNOSIS: To clarify the cause of rapid deterioration of renal function, we performed a renal biopsy. The histology of the renal specimen revealed an unusual type acute bacterial interstitial nephritis most likely due to an infection with E. coli. The clinical picture, the laboratory findings and renal histology, lead to the diagnosis of birenal malakoplakia. TREATMENT AND COURSE: After intravenous and subsequent oral antibiotic therapy the fever and the clinical signs of urosepticaemia subsided and renal function gradually improved. Antibiotic therapy and supplementation with vitamins were continued for 20 weeks. Five years after initial diagnosis, renal function was stable at a glomerular filtration rate of approximately 45 ml/min. CONCLUSIONS: Malakoplakia of the kidney is a rare form of bacterial interstitial nephritis and requires long-term antibiotic therapy.

Acute Kidney Injury↗

Patient based method of assessing adverse events in clinical trials in rheumatology: the revised Stanford Toxicity Index.

We describe the progress towards developing a patient rated toxicity index that meets all of the patient-important attributes defined by the OMERACT Drug Safety Working Party. These attributes are frequency, severity, importance to patient, importance to the clinician, impact on economics, impact on activities, and integration of adverse effects with benefits. The Stanford Toxicity Index (STI) has been revised to collect all attributes with the exception of impact on activities. However, since the STI is a part of the Health Assessment Questionnaire (HAQ), impact on activities is collected by the HAQ. In particular, a new question asks patients to rate overall satisfaction, taking into consideration both benefits and adverse effects. The next step in the development of this tool is to ensure that the STI meets the OMERACT filter of truth, discrimination, and feasibility. Although truth and feasibility have been confirmed by comparisons within the ARAMIS database, discrimination needs to be assessed in clinical trials.

Adverse Drug Reaction Reporting Systems↗

A ureterocutaneous fistula forty years after nephrectomy.

The case of a woman presenting with a ureterocutaneous fistula 40 years after nephrectomy is described. Because of advanced respiratory disease and absence of infective activity, a conservative line of treatment with saline rinse was given. At 3 months follow-up the fistula had become chronic, with a small opening without signs of infection and ultrasound revealed no abscess.

Aged↗

Co-expression of the squamous cell carcinoma antigens 1 and 2 in normal adult human tissues and squamous cell carcinomas.

Squamous cell carcinoma antigen (SCCA) serves as a serological marker for advanced squamous cell carcinomas (SCCs) and as an indicator of therapeutic response. Recent molecular studies show that the SCCA is transcribed by two almost identical tandemly arrayed genes, SCCA1 and SCCA2. These genes are members of the high molecular weight serine proteinase inhibitor (serpin) superfamily. Although SCCA1 and SCCA2 are 92% identical at the amino acid level, they have distinct biochemical properties. Paradoxically, SCCA1 is an inhibitor of papain-like cysteine proteinases, such as cathepsins L, S, and K, whereas SCCA2 inhibits chymotrypsin-like serine proteinases, cathepsin G, and mast cell chymase. Using a new set of discriminatory monoclonal antibodies (MAbs) and polymerase chain reaction (PCR) assay, we showed that SCCA1 and SCCA2 were co-expressed in the suprabasal layers of the stratified squamous epithelium of the tongue, tonsil, esophagus, uterine cervix and vagina, Hassall's corpuscles of the thymus, and some areas of the skin. SCCA1 and SCCA2 also were detected in the pseudo-stratified columnar epithelium of the conducting airways. Examination of squamous cell carcinomas of the lung and head and neck showed that SCCA1 and SCCA2 were co-expressed in moderately and well-differentiated tumors. Moreover, there was no differential expression between these SCCA "isoforms" in normal or malignant tissues. In contrast to previous studies, these data indicated that the expression of SCCA1 and SCCA2 was not restricted to the squamous epithelium and that these serpins may coordinately regulate cysteine and serine proteinase activity in both normal and transformed tissues.

Antibodies, Monoclonal↗

[Perforation of the rectum--caused by blunt injury].

A case of perforation of the rectum in a victim of a car crash who suffered pelvic fracture is reported. Seatbelt use, diagnosis, principles of treatment and complications are reported. Rectal perforations caused by blunt trauma is unusual and has a poor prognosis.

Accidents, Traffic↗

Safety of meloxicam: a global analysis of clinical trials.

Meloxicam is a new preferential cyclooxygenase-2 (COX-2) inhibitor for the treatment of rheumatic disease. This paper presents a global safety analysis of data from meloxicam clinical studies, focusing on gastrointestinal (GI) adverse events. Meloxicam 7.5 and 15 mg (n = 893 and 3282) were compared with piroxicam 20 mg (n = 906), diclofenac 100 mg slow release (n = 324) and naproxen 750-1000 mg (n = 243). With respect to all GI adverse events, meloxicam 7.5 and 15 mg were significantly better than all comparators in a pooled analysis of double-blind studies in rheumatoid arthritis (RA) and osteoarthritis (OA). When examining non-serious GI events, severe GI events, discontinuous due to GI events, dyspepsia, abdominal pain and upper GI events, both meloxicam doses were significantly better than comparator non-steroidal anti-inflammatory drugs (NSAIDs) in most cases. Where statistical significance was not demonstrated, there was generally a trend in favour of meloxicam. With respect to upper GI perforations, ulcerations and bleedings, the most serious of NSAID-associated side-effects, meloxicam was better tolerated than the comparators, reaching statistical significance for piroxicam and naproxen. Meloxicam's improved GI safety profile is likely to be due to its preferential inhibition of inducible COX-2 relative to constitutive COX-1.

Adult↗

Toward an understanding of NSAID-related adverse events: the contribution of longitudinal data.

The ARAMIS (Arthritis, Rheumatism and Ageing Medical Information System) databanks have been used to objectify and quantify drug toxicity. The relative risk of a gastrointestinal (GI)-provoked hospitalization was more than five times greater in patients taking non-steroidal anti-inflammatory drugs (NSAIDs) than in non-NSAID-treated patients, with an excess hospitalization rate of 1.3% per annum. Additionally, there was an excess GI-related death rate of around 3% in rheumatoid arthritis (RA) patients compared with the normal population. Age, previous NSAID-related GI events, prednisone use, higher doses and greater disability predicted high-risk patients. A toxicity index showed clear differences between NSAIDs, with aspirin, salsalate and ibuprofen emerging as the least toxic, and meclofenamate and indomethacin as the most toxic. Disease modifying anti-rheumatic drugs (DMARDs) were, surprisingly, found to have similar toxicity scores to the NSAIDs. This supports the contemporary practice of employing DMARDs earlier and more aggressively in the course of RA.

Aged↗

[Postmyelographic headache].

Prolonged cerebrospinal fluid leakage from the dural puncture site is considered the most important factor in the development of post-myelography headache. Incidences of post-myelography headache and post dural puncture headache vary a lot--possible reasons are discussed. The statement that patients with a low substance P level in cerebrospinal fluid are prone to developing a post dural puncture headache seems especially interesting. Articles considering clinical as well as experimental studies are reviewed.

Contrast Media↗

Helmets on climbers.

Explore the source record for details and available documents.

Craniocerebral Trauma↗

Health status instruments / utilities.

Rheumatologists and other interested professionals at the OMERACT II conference formed small groups to discuss whether it was sensible to use a generic health status instrument in musculoskeletal disease trials. These instruments promise the possibility of comparison of health status between disease states. However, data is lacking on validity of the current generation of instruments to support their use. Participants had little personal experience with these instruments. After inspection, many voiced strong concerns over comprehensiveness and responsiveness. Many dimensions of health relevant for patients with this group of diseases were felt to be underrepresented. The dimension of adverse effects was universally absent, although this is more a problem of state of the art in trial methodology than a problem of these measures. Although there is little data, the small number of response categories in the dimensions covered, plus the lack of comprehensiveness, make it likely that responsiveness will be low. Further research, especially the adoption of one or more generic measures alongside specific measures, both in trials and in observational studies, is necessary to validate and improve the current generic measures. Until that time, valid conclusions and health policy regarding musculoskeletal diseases cannot be based on generic measures of health status.

Health Status↗

Second-trimester echogenic small bowel: an increased risk for adverse perinatal outcome.

2267 singleton fetuses who had one ultrasound examination between 15 and 21 weeks' gestation were prospectively evaluated for echogenic small bowel. Thirty-two cases of echogenic small bowel were detected--a prevalence of 1.4 per cent. Echogenic fetal small bowel was divided into two grades: grade 1, where the small bowel was more echogenic than the liver; and grade 2, where the small bowel had the echogenicity of bone. In contrast to 19/23 fetuses with grade 1 small bowel echogenicity, only 2/9 fetuses with grade 2 echogenic bowel had a normal pregnancy outcome (Fisher's exact test; P < or = 0.01). Complications associated with second-trimester echogenic small bowel included in utero cytomegalovirus infection, second-trimester growth restriction, intrauterine fetal demise, and chromosomal abnormalities. Second-trimester fetal echogenic small bowel is associated with an increased risk of an adverse outcome. The prevalence of perinatal and neonatal complications is significantly greater when small bowel echogenicity approaches that of bone.

Adult↗

Fetal loss rate after ultrasonically documented cardiac activity between 6 and 14 weeks, menstrual age.

The pregnancy outcome of 347 patients with a confirmed, viable intrauterine pregnancy between 6.0 and 14.0 weeks, menstrual age, was determined. The miscarriage rate was 4.2% in a subgroup of patients without vaginal bleeding, as compared with 12.7% in a subgroup with bleeding (chi 2 = 7.4, p less than 0.006). First trimester vaginal bleeding was a significant covariate in the determination of the spontaneous miscarriage rate after fetal cardiac activity has been confirmed.

Abortion, Spontaneous↗

The effect of trisomy 18 on transverse cerebellar diameter.

The transverse cerebellar diameter was measured in 19 fetuses with trisomy 18. Eleven of the cerebellar measurements (57.9%) were greater than 2 SD below the mean for the patient's gestational age. If fetal biometry rather than last menstrual period were used to determine gestational age, four of the 19 (21.0%) cerebellar measurements were greater than 2 SD below the mean. Both intrauterine growth retardation and intrinsic central nervous system abnormalities associated with trisomy 18 appeared to affect cerebellar size.

Cerebellum↗

P & T committee review of misoprostol: prevention of NSAID side effects is key--roundtable discussion.

Misoprostol, a prostaglandin of the E series, was recently introduced for the prevention of NSAID-induced gastric ulcers. Misoprostol was classified as "1A" (denoting a new chemical entity that is a significant therapeutic advance) for purposes of review priority by the Food and Drug Administration in 1988. A dosage of 200 micrograms qid is recommended for prophylaxis, for the duration of NSAID therapy. Misoprostol is generally well-tolerated, with some patients reporting diarrhea. Misoprostol should not be given to pregnant women because of its uterotonic effects. (Please see full prescribing information for a discussion of the safety profile of misoprostol.) Because of the magnitude of the problem of NSAID-induced gastric ulceration and the expense of treatments and hospitalizations, the use of misoprostol in preventing these ulcers should be clinically beneficial, and may contribute to significant cost savings in the hospital and other managed-care settings.

Alprostadil↗